2023-11-14T10:36:57-06:00 2022-12-31 PwC US Tax LLP 655 NEW YORK AVENUE NW STE 1100 WASHINGTON DC 20001 990 2022-01-01 473355381 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY % SARA COBLIN PARK 4159304386 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 MICHAEL POLANSKY EXEC. VP 4159304386 2023-11-10 true MICHAEL POLANSKY 999009999 TRAVIS PATTON P00369623 6464713000 2023-11-08 2 2022 2023-04-26 12:10:37Z UTE DUGAN 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 40446762 false X WWW.PARKERICI.ORG X 2015 CA SEE SCHEDULE O 17 17 92 19 0 0 160955548 691633 9757426 13501237 94889 15719892 188327 2856375 170996190 32769137 9050381 18087363 0 0 20104846 20762093 0 0 79818 23487994 23392196 52643221 62241652 118352969 -29472515 380437987 307154607 52905586 57635216 327532401 249519391 X THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY'S (PICI) MISSION IS TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TURN ALL CANCERS INTO CURABLE DISEASES. false false 53636140 18087363 15598077 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI CONDUCTS ITS OWN RESEARCH AND CLINICAL TRIALS AND PROVIDES ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM. 53636140 true true false false false false false false false false true true true false true true true false false false true true false false false false false true false true false false false true false false false true true false false false true true false false false true 56 0 true 92 true false false false false false false false false false false false false X 17 17 true false false false false true true true true false false true true true true true true true true false CA X SARA COBLIN 6288997600 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 X JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 40.0 0.0 X 854600 0 34231 UTE DUGAN MD CHIEF MEDICAL OFFICER 40.0 0.0 X 751934 0 43380 TARAK MODY CHIEF BUSINESS OFFICER 40.0 0.0 X 586752 0 43381 JUSTIN FAIRCHILD VP CLINICAL DEV. THRU 9/30/22 31.0 0.0 X 535136 0 33360 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 40.0 0.0 X 521356 0 42581 LISA BUTTERFIELD VP RES. & DEV. THRU 7/31/22 24.0 0.0 X 525443 0 29610 SARA COBLIN SR VP FINANCE & ADMIN. 40.0 0.0 X 522112 0 31096 LACEY PADRON VP INFORMATICS 40.0 0.0 X 400026 0 38873 SEAN N PARKER CHAIR OF THE BOARD & DIRECTOR 12.0 6.0 X X 0 0 0 MICHAEL POLANSKY EXECUTIVE VP & DIRECTOR 10.0 6.0 X X 0 0 0 TOM VAN LOBEN SELS TREASURER & DIRECTOR 1.0 0.0 X X 0 0 0 JEFFREY A BLUESTONE PHD VICE CHAIR & DIRECTOR 1.0 0.0 X 0 0 0 TONY COLES MD DIRECTOR 1.0 0.0 X 0 0 0 ERIC ESRAILIAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 SCOTT GOTTLIEB MD DIRECTOR 1.0 0.0 X 0 0 0 BEN HOROWITZ DIRECTOR 1.0 0.0 X 0 0 0 JEFF HUBER DIRECTOR 1.0 0.0 X 0 0 0 BOB HUGIN DIRECTOR 1.0 0.0 X 0 0 0 REED JOBS DIRECTOR 1.0 0.0 X 0 0 0 JOEL MARCUS DIRECTOR 1.0 0.0 X 0 0 0 BOB NELSEN DIRECTOR 1.0 0.0 X 0 0 0 BRUCE PARKER PHD DIRECTOR 1.0 0.0 X 0 0 0 BOB PITTMAN DIRECTOR 1.0 0.0 X 0 0 0 RAMY IBRAHIM MD DIRECTOR 1.0 0.0 X 0 0 0 MARGO GEORGIADIS DIRECTOR 1.0 0.0 X 0 0 0 SUSAN DAWSON SECRETARY 10.0 5.0 X 0 0 0 4697359 0 296512 68 false true false CLINVERSE-CLINPAY PO BOX 419473 BOSTON MA 02241 CLINICAL TRIAL EXP 995915 REGENTS OF UNIV OF CAL SAN FRANC PO BOX 748872 LOS ANGELES CA 90074 PATENT/CLINIC EXP. 979366 LUMA BRIDGE 1305 EAST HOUSTON STREET SAN ANTONIO TX 78205 CLINICAL TRIAL EXP 916343 ARIS CLINICAL 369B 3RD STREET 231 SAN RAFAEL CA 92024 CLINICAL TRIAL EXP 752522 MEMORIAL SLOAN-KETTERING CANCER CTR PO BOX 843899 LOS ANGELES CA 90084 TEST/VALIDATION EXP. 699333 46 691633 622600 691633 RESEARCH STUDY SPONSORSHIP 900099 10876237 10876237 LICENSE FEES 900099 2625000 2625000 13501237 1676519 1676519 0 759535 759535 0 0 0 21720998 7677625 14043373 14043373 14043373 0 0 0 0 0 0 0 0 0 RETENTION TAX CREDIT 900099 2096840 2096840 2096840 32769137 15598077 16479427 17837363 17837363 0 250000 250000 0 2237353 1684145 553208 0 15406447 12067025 3294177 45245 294047 227166 65465 1416 1838442 1317418 515300 5724 985804 792648 190446 2710 0 2278882 1841089 437793 649936 649936 0 0 0 4574258 3334302 1239956 57330 57330 227921 37328 189948 645 1529340 1276661 249091 3588 0 1363504 995358 368146 693179 573274 117714 2191 0 2851722 2848865 2857 0 0 1282007 1282007 201655 201655 INSTITUTION STAFF SUPPORT 984922 984922 0 0 BIOBANKING 653945 653945 0 0 CLINICAL TRIAL SUPPORT 3648131 3648131 0 0 TESTING VALIDATION 1918141 1918141 0 0 477323 66352 392672 18299 62241652 53636140 8525694 79818 8333381 6165490 169344965 107152164 0 0 1330218 3976058 0 0 0 0 0 0 0 0 828130 2444972 8706523 8297111 1691419 409412 1000000 0 15500000 17939587 182409874 165260356 0 0 0 3806568 380437987 307154607 7905586 7888382 0 0 0 875000 0 0 0 0 7000000 7000000 0 0 0 0 38000000 41871834 52905586 57635216 X 318004204 241029023 9528197 8490368 327532401 249519391 380437987 307154607 X -29472515 -47928336 -612159 X false true X true false X MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK NY UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON TX STANFORD MEDICINE STANFORD CA UNIVERSITY OF CALIFORNIA LOS ANGELES LOS ANGELES CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO CA UNIVERSITY OF PENNSYLVANIA PHILADELPHIA PA DANA-FARBER CANCER INSTITUTE BOSTON MA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI NEW YORK NY RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 720271 720271 0 0 7986252 7576840 409412 409412 GEORGIAMUNE INC. 15000000 F APRICITY HEALTH, LLC 407334 F SENTI BIOSCIENCES, INC. 352500 F 3T BIOSCIENCES, INC. 1530855 F SYNCOPATION LIFE SCIENCES, INC 26298 F CARGO THERAPEUTICS, INC. 622600 F 17939587 IMAGINAB (EQUITY INVESTMENT) 1004281 F TMUNITY (EQUITY INVESTMENT) 45431240 F LYELL IMMUNOPHARMA,INC(EQUITY) 25278128 F ARSENAL BIOSCIENCES (EQUITY) 53620874 F AFFINI-T THERAPEUTICS (EQUITY) 11508378 F 3T BIOSCIENCES (EQUITY INVEST) 3104167 F DISPATCH BIO (CONVERT. NOTE) 10071096 F AKAMIS (CONVERTIBLE NOTE) 10242192 F TWAIN (EQUITY INVEST) 5000000 F 165260356 0 CONDITIONAL CONTRIBUTIONS 38000000 LEASE LIABILITY 3871834 41871834 X -15144889 -47928336 14310 -47914026 32769137 32769137 62867811 14310 611849 626159 62241652 62241652 PART X, LINE 2: PICI HAS NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES AS OF DECEMBER 31, 2022 and 2021. PART XII, LINE 2D - OTHER ADJUSTMENTS: GRANT PAID ADJUSTMENT: $611,849 true Europe (Including Iceland and Greenland) 0 0 Program Services RESEARCH SERVICES 491956 Europe (Including Iceland and Greenland) 0 0 Investments 198904 North America 0 0 Program Services RESEARCH SERVICES 17538 East Asia and the Pacific 0 0 Investments 5000000 Europe (Including Iceland and Greenland) 0 0 Grantmaking 250000 0 0 0 0 5958398 5958398 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY 250000 WIRE 1 true false true false false false PART I, LINE 2 PICI AWARDS GRANTS SUBJECT TO A MASTER COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. EACH INSTITUTION SUBMITS PROJECT PROPOSALS WHICH ARE EVALUATED TO ENSURE THEY ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. PART I, LINE 3, NUMBERS (2) AND (4) EACH OF THESE INVESTMENTS ARE PROGRAM-RELATED INVESTMENTS OF PICI. PART I, LINE 3 ACCRUAL BASIS true BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE 1500 E DUARTE ROADE DUARTE CA 91010 953435919 501(C)(3) 21600 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY CHILDREN'S HOSPITAL OF PHILADELPHIA 3401 CIVIC CENTER BLVD PHILADELPHIA PA 19104 232237932 501(C)(3) 360000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02115 042263040 501(C)(3) 10240000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY FHCRC - HUTCHINSON 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 420457 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY ICAHN SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 551172 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY INSTITUTE FOR SYSTEMS BIOLOGY 1801 LIND AVE SW RENTON WA 980579016 912003593 501(C)(3) 547924 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE BOX 69 NEW YORK NY 10065 912154267 501(C)(3) 399355 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 556995 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BLVD STE 620 LOS ANGELES CA 90024 956006143 GOVT 121001 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 GOVT 441669 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WASHINGTON UNIVERSITY 700 ROSEDALE AVENUE CB 1034 SAINT LOUIS MO 63112 430653611 GOVT 998477 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE J DAVID GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501(C)(3) 2563512 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCI 333 CALIFORNIA STREET 315 SAN FRANCISCO CA 94143 946036493 GOVT 615201 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY 13 PART I, LINE 2: PICI AWARDS GRANTS SUBJECT TO A MASTER COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. EACH INSTITUTION SUBMITS PROJECT PROPOSALS WHICH ARE EVALUATED TO ENSURE THEY ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. X X true true X X X X true false false false false false false true false UTE DUGAN MD CHIEF MEDICAL OFFICER 578564 0 172500 0 870 0 9150 0 34230 0 795314 0 0 0 JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 611300 0 167430 0 75870 0 0 0 34231 0 888831 0 0 0 LISA BUTTERFIELD VP RES. & DEV. THRU 7/31/22 249088 0 0 0 276355 0 7032 0 22578 0 555053 0 0 0 JUSTIN FAIRCHILD VP CLINICAL DEV. THRU 9/30/22 299580 0 0 0 235556 0 7687 0 25673 0 568496 0 0 0 TARAK MODY CHIEF BUSINESS OFFICER 450882 0 135000 0 870 0 9150 0 34231 0 630133 0 0 0 LACEY PADRON VP INFORMATICS 283968 0 115000 0 1058 0 4708 0 34165 0 438899 0 0 0 SARA COBLIN SR VP FINANCE & ADMIN. 401242 0 120000 0 870 0 9150 0 21946 0 553208 0 0 0 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 400486 0 120000 0 870 0 9150 0 33431 0 563937 0 0 0 PART I, LINE 1A ANYONE TRAVELING OVER 3000 MILES CAN FLY BUSINESS CLASS OR FIRST CLASS (IF ONLY 2 LEVELS OF SERVICE ARE OFFERED). VP'S CAN TRAVEL BUSINESS OR FIRST CLASS FOR TRAVEL OVER 2000 MILES. PART I, LINE 3 THE CHIEF EXECUTIVE OFFICER POSITION WAS VACANT DURING 2022. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES IN DETERMINING SUCH COMPENSATION: THE BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE REVIEWS ANY PROPOSED COMPENSATION, INCLUDING THE SALARY, OF ITS CHIEF EXECUTIVE OFFICER TO ENSURE THAT, IN EACH CASE, SUCH SALARY IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. PART I, LINE 4A DURING 2022, LISA BUTTERFIELD RECEIVED A SEVERANCE PAYMENT OF $201,841 AND JUSTIN FAIRCHILD RECEIVED A SEVERANCE PAYMENT OF $217,168. PART I, LINE 7 MOST OF PICI'S EMPLOYMENT AGREEMENTS, WHICH ARE NEGOTIATED AT ARMS-LENGTH WITH REFERENCE TO COMPARABILITY DATA, CONTAIN A PROVISION PERMITTING ANNUAL INCENTIVE BONUSES, WHICH ARE CAPPED AT UP TO A FIXED PERCENTAGE. SEAN PARKER CHAIR OF THE BOARD & DIRECTOR OPERATING SUPPORT X 7000000 7000000 false true true 7000000 TWAIN THERAPEUTICS PTE LTD SEE PART V 5000000 SEE PART V false PART II THIS LOAN WAS MADE BY MR. PARKER TO PICI TO ALLOW PICI TO FURTHER ITS TAX-EXEMPT ACTIVITIES. PART IV, LINE 1 TWAIN THERAPEUTICS PTE, LTD IS A 35% CONTROLLED ENTITY OF A FAMILY MEMBER OF KEY EMPLOYEE JOHN CONNOLLY, PHD. THE TRANSACTION WAS THE PURCHASE OF 23,315 SERIES A SHARES OF TWAIN THERAPEUTICS PTE, LTD. THIS INVESTMENT IS A PROGRAM RELATED INVESTMENT OF PICI. A COMMITTEE OF DIRECTORS WITH NO CONFLICT OF INTEREST APPROVED THE INVESTMENT AFTER DETERMINING IT WAS REASONABLE AND FAIR TO PICI, REPRESENTED FAIR VALUE, AND WAS NOT EXCESSIVE WITH REFERENCE TO COMPARABLE CELL THERAPY INVESTMENTS BY COMPARABLE ORGANIZATIONS, AND FURTHER DETERMINING THAT PICI COULD NOT HAVE OBTAINED A MORE ADVANTAGEOUS ARRANGEMENT WITH REASONALBE EFFORT UNDER THE CIRCUMSTANCES. X 1 622600 FMV false true false SCHEDULE M, PART I, COLUMN (B): THE NUMBERS REPORTED IN PART I, COLUMN (B) REPRESENT THE NUMBER OF CONTRIBUTIONS RATHER THAN THE NUMBER OF SHARES RECEIVED. FORM 990, PART I, LINE 1 DESCRIPTION OF ORGANIZATION MISSION: THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) IS RADICALLY CHANGING THE WAY CANCER RESEARCH IS DONE. THE SAN FRANCISCO-BASED NONPROFIT IS AN UNPRECEDENTED COLLABORATION BETWEEN THE COUNTRY'S LEADING IMMUNOTHERAPY RESEARCHERS AND CANCER CENTERS, INCLUDING STANFORD UNIVERSITY, THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE UNIVERSITY OF PENNSYLVANIA, DANA FARBER CANCER INSTITUTE, GLADSTONE INSTITUTES, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, AND MEMORIAL SLOAN KETTERING CANCER CENTER. THE INSTITUTE ALSO SUPPORTS TOP RESEARCHERS AT OTHER INSTITUTIONS, INCLUDING CITY OF HOPE, FRED HUTCHINSON CANCER RESEARCH CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, INSTITUTE FOR SYSTEMS BIOLOGY, WEILL CORNELL MEDICAL COLLEGE, AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS. BY FORGING ALLIANCES WITH ACADEMIC, INDUSTRY, AND NONPROFIT PARTNERS PICI MAKES BIG BETS ON BOLD RESEARCH TO FULFILL ITS MISSION: TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TRANSFORM ALL CANCERS INTO CURABLE DISEASES. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS IS COMPRISED OF ONE 'CLASS A' DIRECTOR WITH THE BALANCE OF THE DIRECTORS SERVING AS 'CLASS B' DIRECTORS. THE CLASS A DIRECTOR MUST BE PRESENT TO CONSTITUTE A QUORUM, UNLESS THE CLASS A DIRECTOR'S RECUSAL IS REQUIRED BY LAW OR CORPORATE POLICY. EACH DIRECTOR IS ENTITLED TO ONE VOTE. ANY ACT OF THE BOARD OF DIRECTORS REQUIRES THE AFFIRMATIVE VOTE OF BOTH THE CLASS A DIRECTOR AND A MAJORITY OF THE CLASS B DIRECTORS PRESENT AT A MEETING AT WHICH A QUORUM IS PRESENT, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS. PICI DOES HAVE AN EXECUTIVE COMMITTEE. IT HAS ALL THE AUTHORITY OF THE BOARD OF DIRECTORS BETWEEN REGULAR AND SPECIAL MEETINGS, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS OR BY THE BOARD OF DIRECTORS IN SPECIFIC INSTANCES. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO AND REVIEWED BY THE BOARD OF DIRECTORS AT ITS NEXT REGULARLY SCHEDULED MEETING. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS HAVE A BUSINESS RELATIONSHIP AND/OR FAMILY RELATIONSHIP: JEFFREY BLUESTONE, JOHN CONNOLLY, SUSAN DAWSON, ERIC ESRAILIAN, SCOTT GOTTLIEB, BEN HOROWITZ, JEFF HUBER, REED JOBS, BOB NELSEN, BRUCE PARKER, SEAN PARKER, BOB PITTMAN, MICHAEL POLANSKY, TOM VAN LOBEN SELS. FORM 990, PART VI, SECTION A, LINE 7A THE DESIGNATOR HAS THE AUTHORITY TO APPOINT MEMBERS OF PICI'S GOVERNING BODY. FORM 990, PART VI, SECTION A, LINE 7B THE DESIGNATOR HAS THE AUTHORITY TO REMOVE MEMBERS OF PICI'S GOVERNING BODY, TO CONSENT TO SUCH REMOVAL BY THE BOARD, AND TO CONSENT TO ANY AMENDMENTS TO PICI'S BYLAWS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD AUTHORIZES AND OVERSEES A REVIEW OF THE ADMINISTRATION OF THE CONFLICT OF INTEREST POLICY. THE REVIEW CONSIDERS THE LEVEL OF COMPLIANCE WITH THE POLICY, THE CONTINUING SUITABILITY OF THE POLICY, AND WHETHER THE POLICY SHOULD BE MODIFIED AND IMPROVED. IF A TRANSACTION ARISES WHERE THERE IS A CONFLICT OF INTEREST, THE PERSON WITH SUCH CONFLICT IS NOT ALLOWED TO VOTE ON THE TRANSACTION NOR BE PRESENT FOR SUCH VOTE. THE CONFLICT OF INTEREST POLICY COVERS EACH DIRECTOR, CORPORATE OFFICER, TOP MANAGEMENT OFFICIAL, TOP FINANCIAL OFFICIAL AND EACH KEY EMPLOYEE OF PICI, AND OTHERS THAT PICI MAY IDENTIFY. FORM 990, PART VI, SECTION B, LINE 15 FORM 990, PART VI, SECTION B, LINE 15A - AS STATED AT SCHEDULE J, PART I, LINE 3, THE CEO POSITION WAS VACANT DURING THE 2022 CALENDAR YEAR. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES: THE BOARD OF DIRECTORS APPROVES THE SALARY OF PICI'S CHIEF EXECUTIVE OFFICER ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. FORM 990, PART VI, SECTION B, LINE 15B THE ORGANIZATION DOES NOT COMPENSATE ITS CORPORATE OFFICERS, BUT ADHERES TO THE FOLLOWING PROCEDURES FOR ITS KEY EMPLOYEES: THE BOARD OF DIRECTORS (OR DULY AUTHORIZED AND INDEPENDENT BOARD COMMITTEE) APPROVES THE SALARY OF PICI'S KEY EMPLOYEES ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATION ORGANIZATIONS. FOR ITS OTHER EMPLOYEES, PICI WORKS WITH A RECRUITER AND, AS PART OF THAT PROCESS, ROUTINELY COMPARES THE PROPOSED SALARY WITH SALARIES PAID BY OTHER ORGANIZATIONS FOR SIMILAR POSITIONS. FORM 990, PART VI, SECTION C, LINE 19 PICI'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE AS REQUIRED BY LAW. FORM 990, PART XI, LINE 9 GRANTS PAID ADJUSTMENT - (611,849) MAVERIC LLC 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 853467441 COVID-19 CLIN CA 0 PICI SEAN N PARKER FOUNDATION 314 LYTTON AVE PALTO ALTO CA 94301 274389819 NONPROFIT SUP CA 501(C)(3) PF NA true ECONOMIC INNOVATION GROUP INC 616 H STREET NW SUITE 550 WASHINGTON DC 20001 462450336 PUBLIC INTERE DC 501(C)(4) N/A NA true false false false false false false false false false false false false false false false false false false PART I, IDENTIFICATION OF DISREGARDED ENTITIES: NAME OF DISREGARDED ENTITY: MAVERIC, LLC ADDRESS: 1 LETTERMAN DRIVE, D3500 SAN FRANCISCO, CA 94129 EIN: 85-3467441 PRIMARY ACTIVITY: COVID-19 CLINICAL TRIAL MANAGEMENT (CURRENTLY INACTIVE) DIRECT CONTROLLING ENTITY: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY SCHEDULE R, SUPPLEMENTAL INFORMATION: THE CLASS A DIRECTOR ALSO HAS A CONTROLLING INTEREST IN SEVERAL PASSIVE INVESTMENT VEHICLES. THESE INVESTMENT VEHICLES AND THE TAX-EXEMPT ENTITIES DISCLOSED UNDER PART II ABOVE MAY TECHNICALLY BE CONSIDERED "RELATED ORGANIZATIONS" OF PICI FOR IRS FORM 990 REPORTING PURPOSES THROUGH THEIR RELATIONSHIP WITH THE CLASS A DIRECTOR. THE PASSIVE INVESTMENT VEHICLES HAVE NO TRANSACTIONS OR BUSINESS RELATIONSHIPS WITH PICI AND ARE NOT DISCLOSED ON SCHEDULE R.